All In MedTech

Device Trial Radar · NCT03076515

Migraine Treatment With Nerivio Migra Neurostimulation Device

A Prospective, Randomized, Double-blind, Sham Controlled Multi-center Clinical Trial, Migraine Headache Treatment With Nerivio Migra Neurostimulation Device

Last checked: Nov 19, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

120

Actual

Start

Apr 2, 2017

Primary completion

Jan 31, 2018

Study completion Apr 1, 2018

Sponsor

Lead sponsor
TheranicaNot on our public-company list
Sponsor type
Industry
First posted
Mar 10, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, double-blind, sham controlled multi-center trial. Ratio between treatment and control groups will be 1:1, stratified by center and use of preventive medications.

Conditions

  • Acute Migraine

Interventions

  • Nerivio Migra neurostimulationDevice

    transcutaneous electrical stimulation

  • Sham Nerivio MigraDevice

    electrical stimulation- shame mode

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Pain Relief 2 Hours Post TreatmentTime frame: 2 hours post treatment

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • MedStar - Georgetown University Hospital

    Washington D.C., District of Columbia

  • Albany Medical College

    Albany, New York

  • Hartford Healthcare Headache Center

    Hartford, New York

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.